16.82
Maze Therapeutics Inc Borsa (MAZE) Ultime notizie
Q2 Earnings Estimate for MAZE Issued By HC Wainwright - Defense World
What analysts say about Maze Therapeutics Inc. stockExceptional profit potential - PrintWeekIndia
Why Maze Therapeutics Inc. stock attracts strong analyst attentionPredictable High Return Trades - Newser
What makes Maze Therapeutics Inc. stock price move sharplyFree Stock Market Entry & Exit Signals - Newser
What institutions are buying Maze Therapeutics Inc. stock nowFree Trading Strategy Suggestions - jammulinksnews.com
What drives Maze Therapeutics Inc. stock priceExtraordinary performance - Autocar Professional
Maze Therapeutics Inc. Stock Analysis and ForecastTremendous wealth creation - Autocar Professional
This Celsius Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
H.C. Wainwright initiates coverage on Maze Therapeutics stock with Buy rating - Investing.com UK
Maze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued Stock - TipRanks
Is Maze Therapeutics Inc. a good long term investmentHigh-velocity gains - Autocar Professional
Maze Therapeutics, Inc.’s (NASDAQ:MAZE) Lock-Up Period To Expire on July 30th - Defense World
how maze therapeutics inc. stock performs during market volatilityDaily Trade Opportunity - Newser
How Maze Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser
Maze Therapeutics (NASDAQ:MAZE) Research Coverage Started at Wedbush - Defense World
Q2 Earnings Estimate for Maze Therapeutics Issued By Wedbush - Defense World
Brokerages Set Maze Therapeutics, Inc. (NASDAQ:MAZE) Target Price at $23.50 - Defense World
Maze Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Maze Therapeutics Showcases Precision Medicine Pipeline at Major Kidney and Biotech Investor Conferences - Stock Titan
Maze Therapeutics Soars 11.68% on Wedbush's Outperform Rating - AInvest
Maze Therapeutics' Development Strategy Using Genetic Validation Seen as Promising, Wedbush Says - MarketScreener
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference - GlobeNewswire
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Analysts Offer Insights on Healthcare Companies: Strata Skin Sciences (SSKN), Ionis Pharmaceuticals (IONS) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):